Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

NCT05885841 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease (CAD)

Interventions

DRUG: XTR004

Sponsor

Sinotau Pharmaceutical Group